| Dapagliflozin and cardiovascular outcomes in type 2 diabetes SD Wiviott, I Raz, MP Bonaca, O Mosenzon, ET Kato, A Cahn, ... New England Journal of Medicine 380 (4), 347-357, 2019 | 6599 | 2019 |
| SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome … TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich, MP Bonaca, ... The Lancet 393 (10166), 31-39, 2019 | 2873 | 2019 |
| Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal … TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich, RHM Furtado, ... Circulation 139 (17), 2022-2031, 2019 | 786 | 2019 |
| Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial O Mosenzon, SD Wiviott, A Cahn, A Rozenberg, I Yanuv, EL Goodrich, ... The lancet Diabetes & endocrinology 7 (8), 606-617, 2019 | 745 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 663 | 2019 |
| Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review TA Zelniker, E Braunwald Journal of the American College of Cardiology 75 (4), 422-434, 2020 | 506 | 2020 |
| Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial TA Zelniker, MP Bonaca, RHM Furtado, O Mosenzon, JF Kuder, ... Circulation 141 (15), 1227-1234, 2020 | 397 | 2020 |
| Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 Trial RHM Furtado, MP Bonaca, I Raz, TA Zelniker, O Mosenzon, A Cahn, ... Circulation 139 (22), 2516-2527, 2019 | 387 | 2019 |
| Angiography after out-of-hospital cardiac arrest without ST-segment elevation S Desch, A Freund, I Akin, M Behnes, MR Preusch, TA Zelniker, C Skurk, ... New England Journal of Medicine 385 (27), 2544-2553, 2021 | 304 | 2021 |
| Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies M Geroldinger-Simic, T Zelniker, W Aberer, C Ebner, C Egger, A Greiderer, ... Journal of Allergy and Clinical Immunology 127 (3), 616-622. e1, 2011 | 290 | 2011 |
| Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review TA Zelniker, E Braunwald Journal of the American College of Cardiology 72 (15), 1845-1855, 2018 | 257 | 2018 |
| Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias MM Hoeper, J Behr, M Held, E Grunig, CD Vizza, A Vonk-Noordegraaf, ... PloS one 10 (12), e0141911, 2015 | 125 | 2015 |
| Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review TA Zelniker, E Braunwald Journal of the American College of Cardiology 75 (4), 435-447, 2020 | 94 | 2020 |
| The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58 O Mosenzon, SD Wiviott, HJL Heerspink, JP Dwyer, A Cahn, EL Goodrich, ... Diabetes Care 44 (8), 1805-1815, 2021 | 93 | 2021 |
| System and method for communication and processing between devices and objects A Thomas, C Riebschlager, J Sikonski, P Jessica, M Benjamin, G Schock, ... US Patent App. 14/316,335, 2015 | 75 | 2015 |
| The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry TA Zelniker, D Huscher, A Vonk-Noordegraaf, R Ewert, TJ Lange, H Klose, ... Clinical Research in Cardiology 107, 460-470, 2018 | 70 | 2018 |
| Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58 MP Bonaca, SD Wiviott, TA Zelniker, O Mosenzon, DL Bhatt, LA Leiter, ... Circulation 142 (8), 734-747, 2020 | 68 | 2020 |
| Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial O Mosenzon, I Raz, SD Wiviott, M Schechter, EL Goodrich, I Yanuv, ... Diabetes Care 45 (10), 2350-2359, 2022 | 53 | 2022 |
| Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes: a prespecified secondary … TA Zelniker, I Raz, O Mosenzon, JP Dwyer, HHJL Heerspink, A Cahn, ... JAMA cardiology 6 (7), 801-810, 2021 | 51 | 2021 |
| Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor … TA Zelniker, DA Morrow, O Mosenzon, EL Goodrich, P Jarolim, ... European journal of heart failure 23 (6), 1026-1036, 2021 | 48 | 2021 |
